Trial Profile
IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms PHI 05
- 08 Sep 2021 Status changed from active, no longer recruiting to completed.
- 04 Jun 2021 Planned End Date changed from 1 Jul 2021 to 31 Dec 2021.
- 05 May 2020 Status changed from recruiting to active, no longer recruiting.